IMVT · Company research

Immunovant, Inc.

3 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsIMVTImmunovantH2 2026

Immunovant expects to report results from its Phase 2 study of IMVT-1402 (anti-FcRn) for Cutaneous lupus erythematosus in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.

More details

Entry

IMVT-1402 proof-of-concept topline in cutaneous lupus (CLE) · Clinical trial results (readout / topline data)

Drug

IMVT-1402 (anti-FcRn)

For

Cutaneous lupus erythematosus

Stage

Phase 2 · the stage that tests whether the drug actually works

When

H2 2026 · the company gave a window, not a day

Source note

Fiscal Q1 update (Aug 6, 2026): topline proof-of-concept data expected in second half of calendar year 2026; D2T RA registrational program update also expected 2H 2026.

Checked

Checked by a person when it was added

Verify it

Source: immunovant.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
IMVT headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneIMVTImmunovantH2 2026

IMVT-1402 difficult-to-treat RA registrational program update, expected in the second half of 2026 (no exact date yet). A company milestone for Immunovant (IMVT-1402 for difficult-to-treat rheumatoid arthritis): a step in the program rather than a decision or a data readout.

More details

Entry

IMVT-1402 difficult-to-treat RA registrational program update · Company milestone

Drug

IMVT-1402

For

difficult-to-treat rheumatoid arthritis

Stage

potentially registrational · a study designed to support approval

When

H2 2026 · the company gave a window, not a day

Source note

Fiscal Q1 2027 results PR (Aug 6, 2026). The CLE PoC topline (2H26) is already tracked; this is the separate D2T RA program update guided for the same window.

Checked

Checked by a person when it was added

Verify it

Source: immunovant.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
IMVT headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsIMVTImmunovant2027

Immunovant expects to report results from its Potentially registrational study of IMVT-1402 (anti-FcRn) for Graves' disease during 2027 (no exact date yet). Potentially registrational is a study designed to support approval.

More details

Entry

IMVT-1402 registrational topline in Graves' disease · Clinical trial results (readout / topline data)

Drug

IMVT-1402 (anti-FcRn)

For

Graves' disease

Stage

Potentially registrational · a study designed to support approval

When

2027 · the company gave a window, not a day

Source note

Company guidance (Aug 6, 2026): topline data from the potentially registrational Graves' trial expected in calendar year 2027 (year-level precision only).

Checked

Checked by a person when it was added

Verify it

Source: immunovant.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
IMVT headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

MilestoneIMVTImmunovantMay 20, 2026

Immunovant discontinues batoclimab across all indications after TED failure, on May 20, 2026. A company milestone for Immunovant (batoclimab; IMVT-1402 for All batoclimab indications; difficult-to-treat rheumatoid arthritis): a step in the program rather than a decision or a data readout.

More details

Entry

Immunovant discontinues batoclimab across all indications after TED failure · Company milestone

Drug

batoclimab; IMVT-1402

For

All batoclimab indications; difficult-to-treat rheumatoid arthritis

Stage

Phase 3 · the last stage before a drug can be approved

When

May 20, 2026

Source note

Alongside fiscal year results, Immunovant confirmed it had discontinued all further development of batoclimab to focus entirely on IMVT-1402, and disclosed preliminary Week 16 IMVT-1402 data in difficult-to-treat rheumatoid arthritis (ACR20/50/70 of 72.7%/54.5%/35.8%).

Checked

Checked by a person when it was added

Verify it

Source: immunovant.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
IMVT headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsIMVTImmunovantApr 2, 2026

Immunovant reported results from its Phase 3 study of batoclimab for Thyroid eye disease (TED) on Apr 2, 2026. The study missed its main goal.

More details

Entry

Two Phase 3 batoclimab studies missed primary endpoint in thyroid eye disease · Clinical trial results (readout / topline data)

Drug

batoclimab

For

Thyroid eye disease (TED)

Stage

Phase 3 · the last stage before a drug can be approved

When

Apr 2, 2026

Source note

Immunovant's two Phase 3 GO studies of batoclimab in active, moderate-to-severe thyroid eye disease failed to meet the primary endpoint of proptosis responder rate at Week 24. The miss triggered a major repricing of the batoclimab franchise.

Checked

Checked by a person when it was added

Verify it

Source: immunovant.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
IMVT headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to IMVT.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.